Icatibant Viatris (Icatibant)

Icatibant is a competitive antagonist of the bradykinin B2 receptor. It prevents bradykinin from binding to this receptor, thereby inhibiting the cascade that leads to vasodilation and increased vascular permeability, which are responsible for the swelling seen in HAE attacks.

The specific dose and administration schedule are determined by the prescribing healthcare professional based on the patient’s condition, severity of the attack, and clinical guidelines. Patients should follow the prescriber’s instructions precisely.

Safety data for Icatibant in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician after a thorough risk‑benefit assessment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and necessary import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas other options such as C1‑esterase inhibitor concentrates act by replacing deficient plasma proteins. Icatibant offers rapid subcutaneous administration and targets the downstream mediator bradykinin directly, providing an alternative mechanism of action.

Icatibant should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability.

Icatibant is given by subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a trained healthcare professional or, after proper instruction, by the patient or caregiver at the onset of an HAE attack.

Serious risks include hypersensitivity reactions such as rash, urticaria, or anaphylaxis, as well as rare events like severe injection‑site necrosis, thrombocytopenia, and acute hypotension. Patients should be monitored for these signs and seek immediate medical attention if they occur.

Icatibant is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Caution is also advised for individuals with severe cardiovascular disease, uncontrolled hypertension, or those taking ACE inhibitors or ARBs without appropriate medical supervision.